Search research articles
Contact Us
Filters
Showing results (1-10 of 340) with videos related to
Page
of 34
Sort By:
Blood
|
January 8, 2011
TMLI: a better TBI or more of the same?
Sergio Giralt
Nature Reviews. Clinical Oncology
|
August 28, 2010
200 mg/m(2) melphalan--the gold standard for multiple myeloma
Sergio Giralt
Current Hematology Reports
|
April 17, 2004
Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
Sergio Giralt
Hematology. American Society of Hematology. Education Program
|
November 24, 2005
Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?
Sergio Giralt
Seminars in Oncology
|
May 25, 2006
The role of alemtuzumab in nonmyeloablative hematopoietic transplantation
Sergio Giralt
Journal of Oncology Practice
|
September 14, 2016
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?
Sergio Giralt
Blood
|
February 13, 2010
A TAD better for myeloma therapy?
Sergio Giralt
Clinical Lymphoma & Myeloma
|
March 27, 2007
Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date
Sergio Giralt
Clinical Lymphoma & Myeloma
|
September 26, 2009
Advances in stem cell transplantation: making it better and safer
Sergio Giralt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Graft-versus-host disease: have we solved the problem?
Sergio Giralt
Page
of 34
Search research articles
Search
Showing results (1-10 of 340) with videos related to
Sort By:
Page
of 34
Blood
|
January 8, 2011
TMLI: a better TBI or more of the same?
Sergio Giralt
Nature Reviews. Clinical Oncology
|
August 28, 2010
200 mg/m(2) melphalan--the gold standard for multiple myeloma
Sergio Giralt
Current Hematology Reports
|
April 17, 2004
Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
Sergio Giralt
Hematology. American Society of Hematology. Education Program
|
November 24, 2005
Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?
Sergio Giralt
Seminars in Oncology
|
May 25, 2006
The role of alemtuzumab in nonmyeloablative hematopoietic transplantation
Sergio Giralt
Journal of Oncology Practice
|
September 14, 2016
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?
Sergio Giralt
Blood
|
February 13, 2010
A TAD better for myeloma therapy?
Sergio Giralt
Clinical Lymphoma & Myeloma
|
March 27, 2007
Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date
Sergio Giralt
Clinical Lymphoma & Myeloma
|
September 26, 2009
Advances in stem cell transplantation: making it better and safer
Sergio Giralt
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2012
Graft-versus-host disease: have we solved the problem?
Sergio Giralt
Page
of 34